PharmaTher Holdings 관리

관리 기준 확인 2/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

Fabio Chianelli

최고 경영자

CA$360.0k

총 보상

CEO 급여 비율	n/a
CEO 임기	4.4yrs
CEO 소유권	17.5%
경영진 평균 재임 기간	데이터 없음
이사회 평균 재임 기간	4.4yrs

최근 관리 업데이트

Recent updates

CEO

Fabio Chianelli (46 yo)

4.4yrs

테뉴어

CA$360,000

보상

Mr. Fabio Chianelli is the Founder of PharmaTher Holdings Ltd. (formerly known as Newscope Capital Corporation) (formerly known as PharmaTher Inc.). and serves as its Chief Executive Officer since June 03,...

이사회 구성원

이름	위치	테뉴어	보상	소유권
Fabio Chianelli	Founder	4.4yrs	CA$360.00k	17.52% $ 2.7m
Beverly Incledon	Independent Director	4.4yrs	데이터 없음	데이터 없음
Carlo Sansalone	Independent Director	4.4yrs	데이터 없음	1.13% $ 175.2k
Christian Scovenna	Independent Director	4.4yrs	데이터 없음	데이터 없음

4.4yrs

평균 재임 기간

48.5yo

평균 연령

경험이 풍부한 이사회: PHRR.F 의 이사회는 경험(평균 재직 기간 4.4 년)으로 간주됩니다.

PharmaTher Holdings 관리

관리 기준 확인 2/4

주요 정보

최근 관리 업데이트

PharmaTher Holdings Ltd., Annual General Meeting, Nov 29, 2024

PharmaTher Holdings Ltd., Annual General Meeting, Nov 24, 2023

PharmaTher Holdings Ltd., Annual General Meeting, Nov 25, 2022

Recent updates

PharmaTher Holdings Ltd., Annual General Meeting, Nov 29, 2024

PharmaTher Holdings Ltd. Announces Update on FDA New Drug Application for Ketamine

PharmaTher Holdings Ltd. Announces Assigned FDA Approval Goal Date of its Priority Original Abbreviated New Drug Application for Ketamine

PharmaTher Holdings Ltd. Provides Update of Its Priority Original Abbreviated New Drug Application for Ketamine

PharmaTher Holdings Ltd. Provides Update of Its Priority Original Abbreviated New Drug Application for Ketamine

PharmaTher Holdings Ltd. Provides an Update for Its Lead Drug, Ketamine

PharmaTher Holdings Ltd. Announces FDA Acceptance, As a Priority Original Abbreviated New Drug Application, for KETARX(TM) (Ketamine)

PharmaTher Holdings Ltd., Annual General Meeting, Nov 24, 2023

PharmaTher Holdings Ltd. Submits Priority Original Abbreviated New Drug Application for KETARX™ (Ketamine) to the FDA

PharmaTher Holdings Ltd. Announces Positive Research Results for PharmaPatch with N,N-Dymethyltryptamine (DMT) and Strategic Investment into Sairiyo Therapeutics

PharmaTher Holdings Ltd. Initiates Filing of Abbreviated New Drug Application for KETARX to the FDA

New major risk - Share price stability

PharmaTher Holdings Ltd. Announces FDA Approval for KETARX

PharmaTher Holdings Ltd. Submits FDA Meeting Package to Discuss 505(B)(2) Pathway for New Drug Application of Ketarx (Ketamine) On-Body Pump System

PharmaTher Holdings Submits FDA Meeting Package to Discuss Phase 3 Program and Fast Track Designation for KETARX (Ketamine) in Parkinson's Disease

PharmaTher Holdings Ltd. Provides Update for KETARX™ (Racemic Ketamine) Development Programs and Expected Milestones for 2023

Pharmather Holdings Ltd. Announces A Poster Presentation of the Phase 1/2 Clinical Study of Ketamine in the Treatment of Levodopa-Induced Dyskinesia in Parkinson’S Disease

PharmaTher Holdings Ltd. to Present Positive Efficacy and Safety Data from Phase 1/2 Clinical Study of Ketamine in the Treatment of Levodopa-Induced Dyskinesia in Parkinson's Disease At the MDS International Congress of Parkinson's Disease and Movement Disorders

PharmaTher Holdings Ltd., Annual General Meeting, Nov 25, 2022

PharmaTher Holdings Ltd. Announces Completion of IND-Enabling Pharmacokinetic and Tolerability Study with Ketarx Ketamine Patch

PharmaTher Holdings Ltd Announces Notice of Allowance for U.S. Patent Covering Ketamine for the Potential Treatment of Parkinson's Disease and Motor Disorders

PharmaTher Holdings Ltd. Announces Positive Results from Study for Ketamine Microneedle Patch

PharmaTher Holdings Ltd. Announces Positive Results from Study of Ketabet™ for Depression

PharmaTher Holdings Ltd. Announces FDA Approval of Investigational New Drug Application for Ketamine to Treat ALS

PharmaTher Holdings Ltd. Announces Publication of Research Data for Ketabet™

PharmaTher Holdings Ltd Provides Product Pipeline Update and Expected Milestones for 2022

PharmaTher Enters Into Process Development Agreement With LTS LOHMANN for Ketamine Microneedle Patch

PharmaTher Holdings Ltd. Applies for FDA Orphan Drug Designation for Ketamine to Treat Rare Neurological Disorder Status Epilepticus

PharmaTher Holdings Ltd. announced that it expects to receive CAD 10 million in funding

Pharmather Holdings Ltd. Provides Product Pipeline Update

PharmaTher Holdings Ltd. Expands Psychedelic Patent Portfolio with Filing of U.S. Patent Application for Novel Ketamine Formulation

PharmaTher Holdings Ltd. Files FDA Pre-IND Meeting Request and Briefing Package for KETABET™ to Treat Depression

Pharmather Holdings Ltd. Provides Research and Development Update and Milestones for 2021

Pharmather Files for FDA Orphan Drug Designation for Ketamine to Treat Lou Gehrig’s Disease

PharmaTher Announces FDA Approval of Ketamine IND in the Treatment of Parkinson’s Disease

PharmaTher Holdings Expands Patent Portfolio with Filing of U.S. Patent Application for Ketamine and Repurposing of Psychedelics with panaceAI™

PharmaTher Inc. Expands to Neuromuscular Diseases with Exclusive License Agreement for Ketamine in the Treatment of Lou Gehrig's Disease

PharmaTher Announces Research Collaboration with Terasaki Institute for Novel Microneedle Delivery of Psychedelic Pharmaceuticals

Newscope Capital Corporation Announces Successful Completion of a Type B Pre-Investigational New Drug

CEO

테뉴어

보상

이사회 구성원

평균 재임 기간

평균 연령